Lupus and SARS-CoV-2: What have we learned after the pandemic?

Lupus and SARS-CoV-2: What have we learned after the pandemic?

Publication date: Dec 17, 2024

After the end of the COVID-19 public health emergency, we analysed the relationship between Systemic Lupus Erythematosous (SLE) and COVID-19 from the virologist’s perspective based on recent findings. SLE and COVID-19 co-morbidity present unique challenges, as individuals with SLE may be at increased risk for severe COVID-19 illness due to immune system abnormalities and ongoing therapies. Effective management of both diseases requires careful monitoring, adherence to vaccination programs, preventive measures and approved and patient-tailored therapies. This review covers various aspects, including the clinical outcome of SLE patients infected by SARS-CoV-2, the impact of this infection on SLE onset or flare-ups and the benefits of vaccination for this population. Furthermore, this review presents the most recent recommendations on clinical management of COVID-19 in rheumatic patients, including those with SLE, discussing the currently available therapeutic options. Finally, we explore the most effective tools for SARS-CoV-2 diagnosis in autoimmune conditions and examine prognostic biomarkers in COVID-19 rheumatic patients with potential implications on their clinical oversight. By adopting a comprehensive approach, we address these complexities from the virologist’s perspective, aiming to improve health care for this vulnerable population.

Concepts Keywords
Biomarkers biomarkers
Covid COVID-19 drug treatment
Severe COVID-19 testing
Vaccination COVID-19 vaccines
SARS-cov-2
Systemic lupus erythematosus

Semantics

Type Source Name
disease MESH COVID-19
disease MESH emergency
disease MESH morbidity
pathway REACTOME Immune System
disease MESH abnormalities
disease MESH infection
disease MESH Long Covid
disease MESH Systemic lupus erythematosus
pathway KEGG Systemic lupus erythematosus

Original Article

(Visited 1 times, 1 visits today)